We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Stock Moves -0.16%: What You Should Know
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $149.55, moving -0.16% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.43%. At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.9%.
The kidney dialysis provider's stock has dropped by 8.52% in the past month, falling short of the Medical sector's loss of 7.03% and the S&P 500's loss of 1.98%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company's earnings per share (EPS) are projected to be $2.21, reflecting a 18.18% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $3.25 billion, up 3.47% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $9.71 per share and a revenue of $12.8 billion, demonstrating changes of +14.64% and +5.45%, respectively, from the preceding year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, DaVita HealthCare holds a Zacks Rank of #3 (Hold).
In the context of valuation, DaVita HealthCare is at present trading with a Forward P/E ratio of 15.42. This expresses a discount compared to the average Forward P/E of 21.55 of its industry.
It is also worth noting that DVA currently has a PEG ratio of 0.85. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Outpatient and Home Healthcare was holding an average PEG ratio of 2.08 at yesterday's closing price.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 163, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Stock Moves -0.16%: What You Should Know
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $149.55, moving -0.16% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.43%. At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.9%.
The kidney dialysis provider's stock has dropped by 8.52% in the past month, falling short of the Medical sector's loss of 7.03% and the S&P 500's loss of 1.98%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company's earnings per share (EPS) are projected to be $2.21, reflecting a 18.18% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $3.25 billion, up 3.47% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $9.71 per share and a revenue of $12.8 billion, demonstrating changes of +14.64% and +5.45%, respectively, from the preceding year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, DaVita HealthCare holds a Zacks Rank of #3 (Hold).
In the context of valuation, DaVita HealthCare is at present trading with a Forward P/E ratio of 15.42. This expresses a discount compared to the average Forward P/E of 21.55 of its industry.
It is also worth noting that DVA currently has a PEG ratio of 0.85. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Outpatient and Home Healthcare was holding an average PEG ratio of 2.08 at yesterday's closing price.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 163, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.